Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).

MLA

Gisondi, Paolo, et al. “Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).” Dermatology & Therapy, vol. 13, no. 6, June 2023, pp. 1389–90. EBSCOhost, https://doi.org/10.1007/s13555-023-00934-y.

APA

Gisondi, P., Gottlieb, A. B., Elewski, B., Augustin, M., McBride, S., Tsai, T.-F., de la Loge, C., Fierens, F., López Pinto, J. M., Tilt, N., & Lebwohl, M. (2023). Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2). Dermatology & Therapy, 13(6), 1389–1390. https://doi.org/10.1007/s13555-023-00934-y

Chicago

Gisondi, Paolo, Alice B. Gottlieb, Boni Elewski, Matthias Augustin, Sandy McBride, Tsen-Fang Tsai, Christine de la Loge, et al. 2023. “Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).” Dermatology & Therapy 13 (6): 1389–90. doi:10.1007/s13555-023-00934-y.